This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To compare IRC-assessed events-free survival (EFS) in 2 arms
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months